Please login or register first to view this content.
Gastrohepatic Disorders Resource Center
Drug Monographs
Click on the subsection below to see prescribing information
NEWS & FEATURES
OTC Laxative Recalled Due to Microbial Contamination
Skyrizi Approved for Moderately to Severely Active Crohn Disease
Amvuttra Approved for Polyneuropathy of Hereditary Transthyretin-Mediated Amyloidosis
Safety, Efficacy of Oral Microbiome Therapeutic Confirmed in Recurrent CDI Study
Antacid, Constipation Products Recalled Due to Microbial Contamination
May 2022: Drug Pipeline Updates
Opdivo-Based Regimens Approved as First-Line Treatments for Esophageal Cancer
FDA Approves OTC Omeprazole in Mini Capsule Form
Ervogastat/Clesacostat Fast Tracked for Nonalcoholic Steatohepatitis
FDA to Review Vonoprazan for Erosive Esophagitis
Dupixent Gets FDA Approval for Eosinophilic Esophagitis
Upadacitinib Meets Endpoints in Crohn Disease Maintenance Trial
Durvalumab Plus Chemo Granted Priority Review for Biliary Tract Cancer
Voquezna Triple, Dual Pak Approved for H. Pylori Infection Treatment
Zerbaxa Approved for Complicated Pediatric Intra-abdominal, Urinary Tract Infections
WHO Says Acute Hepatitis Cases in Children Now Reported in 11 Countries
No Increased Risk for Appendicitis Reported With mRNA COVID-19 Vaccination
Combo Immunotherapy Gets Priority Review for Advanced Liver Cancer